The DIEP Flap as a Model of Ischemia-Reperfusion: an Intervention Study
NCT ID: NCT00821158
Last Updated: 2009-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
30 participants
INTERVENTIONAL
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?
NCT00457405
Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques
NCT06957821
Cardiovascular Inflammation Reduction Trial
NCT01594333
Effect of Fluvastatin on Brown Fat Activity
NCT03189511
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
NCT05009862
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Placebo tablet and iv
Placebo
Placebo tablet and iv
2
Placebo tablet and intervention iv
Antioxidant
Antioxidant iv bolus
3
Intervention tablet and placebo iv
Anti-inflammatory drug
Anti-inflammatory tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antioxidant
Antioxidant iv bolus
Placebo
Placebo tablet and iv
Anti-inflammatory drug
Anti-inflammatory tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Kidney or liver disease
* Use of immunosuppressants
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maastricht University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maastricht University Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
R. van der Hulst, M.D., Phd
Role: STUDY_CHAIR
Maastricht Universtity Medical Center
Marieke van den Heuvel, M.D.
Role: PRINCIPAL_INVESTIGATOR
Maastricht University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maastricht University Medical Center
Maastricht, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEC 25-11-2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.